Erratum to: Stem cell-derived extracellular vesicle therapy for acute brain insults and neurodegenerative diseases

Abstract

[Erratum to: BMB Reports 2022; 55(1): 20-29, PMID: 35000673] This article was republished on 30 April 2022, to correct the online version of the article which displayed an incorrect References. After online publication of this article, the authors noticed an error in the missing reference section for the page 21 and the Figure 1. The correct statement of this article should have read as below. 1. Our pre-specified biomarker sub-study showed that circulating EVs were markedly increased immediately after intravenous injection of MSCs (10). In this study, the number of the circulating EVs varied among patients after the application of the same dose of MSCs, and was associated with motor function improvement, as assessed by clinical assessment and multimodal magnetic resonance imaging (MRI) as shown in Fig. 1 (10). 2. Fig. 1. Association between elevated levels of circular extracellular vesicles (EVs) and stroke outcome after mesenchymal stem cell (MSC) injection. Modified from Bang et al. (10) 3. Adding a Reference 10. Bang OY, Kim EH, Cho YH et al (2022) Circulating extracellular vesicles in stroke patients treated with mesenchymal stem cells: a biomarker analysis of a randomized trial. Stroke [Epub Ahead of Print], https://doi.org/10.1161/STROKEAHA.121.036545 The authors apologize for any inconvenience caused. The References of Original PDF version have been corrected.